Combining phenome-driven drug-target interaction prediction with patients’ electronic health records-based clinical corroboration toward drug discovery
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Motivation: Predicting drug–target interactions (DTIs) using human phenotypic data have the potential in eliminating the translational gap between animal experiments and clinical outcomes in humans. One challenge in human phenome-driven DTI predictions is integrating and modeling diverse drug and disease phenotypic relationships. Leveraging large amounts of clinical observed phenotypes of drugs and diseases and electronic health records (EHRs) of 72 million patients, we developed a novel integrated computational drug discovery approach by seamlessly combining DTI prediction and clinical corroboration. Results: We developed a network-based DTI prediction system (TargetPredict) by modeling 855 904 phenotypic and genetic relationships among 1430 drugs, 4251 side effects, 1059 diseases and 17 860 genes. We systematically evaluated TargetPredict in de novo cross-validation and compared it to a state-of-the-art phenome-driven DTI prediction approach. We applied TargetPredict in identifying novel repositioned candidate drugs for Alzheimer’s disease (AD), a disease affecting over 5.8 million people in the United States. We evaluated the clinical efficiency of top repositioned drug candidates using EHRs of over 72 million patients. The area under the receiver operating characteristic (ROC) curve was 0.97 in the de novo cross-validation when evaluated using 910 drugs. TargetPredict outperformed a state-of-the-art phenome-driven DTI prediction system as measured by precision–recall curves [measured by average precision (MAP): 0.28 versus 0.23, P-value < 0.0001]. The EHR-based case–control studies identified that the prescriptions top-ranked repositioned drugs are significantly associated with lower odds of AD diagnosis. For example, we showed that the prescription of liraglutide, a type 2 diabetes drug, is significantly associated with decreased risk of AD diagnosis [adjusted odds ratios (AORs): 0.76; 95% confidence intervals (CI) (0.70, 0.82), P-value < 0.0001]. In summary, our integrated approach that seamlessly combines computational DTI prediction and large-scale patients’ EHRs-based clinical corroboration has high potential in rapidly identifying novel drug targets and drug candidates for complex diseases. Availability and implementation: nlp.case.edu/public/data/TargetPredict.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2019 Alzheimer’s disease facts and figures.
Alzheimer's Association (2019) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2019.01.010 · Cited by 2,461
Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database
Bertram, L., McQueen, M. B., Mullin, K., Blacker, D., & Tanzi, R. E. (2007) · Nature Genetics · doi:10.1038/ng1934 · Cited by 1,857
Predicting new molecular targets for known drugs
Keiser, M. J., Setola, V., Irwin, J. J., Laggner, C., Abbas, A. I., Hufeisen, S. J., Jensen, N. H., Kuijer, M. B., Matos, R. C., Tran, T. B., et al. (2009) · Nature · doi:10.1038/nature08506 · Cited by 1,667
Drug target identification using side-effect similarity
Campillos, M., Kuhn, M., Gavin, A.-C., Jensen, L. J., & Bork, P. (2008) · Science · doi:10.1126/science.1158140 · Cited by 1,248
Drug–target interaction prediction: databases, web servers and computational models
Chen, X., Yan, C. C., Zhang, X., Zhang, X., Dai, F., Yin, J., & Zhang, Y. (2016) · Briefings in Bioinformatics · doi:10.1093/bib/bbv066 · Cited by 658
LOINC, a Universal Standard for Identifying Laboratory Observations: A 5-Year Update
McDonald, C. J., Huff, S. M., Suico, J. G., Hill, G., Leavelle, D., Aller, R., Forrey, A., Mercer, K., DeMoor, G., Hook, J., et al. (2003) · Clinical Chemistry · doi:10.1373/49.4.624 · Cited by 579 · cited 1×
“Laboratory tests were normalized by logical observation identifier names and codes (McDonald et al., 2003).”
MethodA randomized controlled trial of prednisone in Alzheimer’s disease
Aisen, P. S., Davis, K. L., Berg, J. D., Schafer, K., Campbell, K., Thomas, R. G., Weiner, M. F., Farlow, M. R., Sano, M., Grundman, M., et al. (2000) · Neurology · doi:10.1212/wnl.54.3.588 · Cited by 464
Haag, M. D. M., Hofman, A., Koudstaal, P. J., Stricker, B. H. C., & Breteler, M. M. B. (2009) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2008.150433 · Cited by 393
Zhou, M., Xu, R., Kaelber, D. C., & Gurney, M. E. (2020) · PLOS ONE · doi:10.1371/journal.pone.0229819 · Cited by 157
Self-citation
Cited by
Wang, Q. Q., Kaelber, D. C., Xu, R., & Volkow, N. D. (2021) · Molecular Psychiatry · doi:10.1038/s41380-020-00880-7 · Cited by 634
Self-citationWang, Q., Xu, R., & Volkow, N. D. (2021) · World Psychiatry · doi:10.1002/wps.20806 · Cited by 617
Self-citationWang, Q., Berger, N. A., & Xu, R. (2021) · JAMA Oncology · doi:10.1001/jamaoncol.2020.6178 · Cited by 390
Self-citationApplication of Artificial Intelligence In Drug-target Interactions Prediction: A Review
Liao, Q., Zhang, Y., Chu, Y., Ding, Y., Liu, Z., Zhao, X., Wang, Y., Wan, J., Ding, Y., Tiwari, P., et al. (2025) · npj Biomedical Innovations · doi:10.1038/s44385-024-00003-9 · Cited by 82
The use of real-world data in drug repurposing
Park, K. (2021) · Translational and Clinical Pharmacology · doi:10.12793/tcp.2021.29.e18 · Cited by 22
Metadata
- Authors
- Zhou, M., Zheng, C., & Xu, R.
- Venue
- Bioinformatics
- Publisher
- Oxford University Press (OUP)
- Published
- 2020-07-01
- Volume
- 36
- Issue
- Supplement_1
- Pages
- i436-i444
- ISSN
- 1367-4803 (ISSN-L)
- 1367-4811
- OpenAlex
- W3042558069
- Cited by
- 34
- References
- 9
- FWCI
- 3.34
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.